ANIK Share Price

Open 44.38 Change Price %
High 44.70 1 Day 0.69 1.58
Low 43.84 1 Week 0.18 0.41
Close 44.47 1 Month 2.12 5.01
Volume 108578 1 Year -2.90 -6.12
52 Week High 54.96
52 Week Low 41.38
ANIK Important Levels
Resistance 2 45.27
Resistance 1 44.94
Pivot 44.34
Support 1 44.00
Support 2 43.67
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
SIRI 5.13 1.18%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
CYTR 0.83 36.07%
SUSQ 14.20 -0.77%
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
CPSL 0.09 50.00%
LOCM 0.09 50.00%
RITT 0.03 50.00%
OPTT 2.74 49.73%
CYTR 0.83 36.07%
WRES 0.09 28.57%
BSDM 0.62 26.53%
ATRM 1.89 26.00%
SNTA 0.34 25.93%
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%

Anika Therapeutics Inc. (NASDAQ: ANIK)

ANIK Technical Analysis 3
As on 24th Apr 2017 ANIK Share Price closed @ 44.47 and we RECOMMEND Sell for LONG-TERM with Stoploss of 47.66 & Sell for SHORT-TERM with Stoploss of 45.62 we also expect STOCK to react on Following IMPORTANT LEVELS.
ANIK Target for April
1st Target up-side 46.85
2nd Target up-side 49.24
3rd Target up-side 51.63
1st Target down-side 40.03
2nd Target down-side 37.64
3rd Target down-side 35.25
ANIK Other Details
Segment EQ
Market Capital 156245312.00
Sector Healthcare
Industry Biotechnology
Offical website
ANIK Address
32 Wiggins Avenue
Bedford, MA 01730
United States
Phone: 781-457-9000
Fax: 781-305-9720
ANIK Latest News
Anika Therapeutics Inc (ANIK) Shares Sold by Baltimore Washington Financial ...   BBNS   - 18th Apr 17
Anika Therapeutics Inc (ANIK): What does the future look like?   Simply Wall St   - 13th Apr 17
-T To Relieve Pain and Restore Function of Tendons Damaged by Chronic Injury   Business Wire (press release)   - 20th Dec 16
Anika Therapeutics Wins CE Mark Approval for Cingal   Business Wire (press release)   - 28th Mar 16
Anika Therapeutics, Inc. Announces First Patient Enrolled in FastTRACK Phase ...   Business Wire (press release)   - 30th Dec 15
Why Anika Therapeutics Gained 13% in July   Motley Fool   - 08th Aug 15
Anika Therapeutics: US Approval To Drive Profit And Valuation   Seeking Alpha   - 23rd Dec 14
Anika Therapeutics, Inc Surges On Approval, but Is It Overpriced Now?   Motley Fool   - 03rd Mar 14
Why Anika Therapeutics Inc. Shares Skyrocketed   Motley Fool   - 26th Feb 14
Anika Therapeutics Inc. ANIK (US: Nasdaq)   Wall Street Journal   - 11th Feb 11
Interactive Technical Analysis Chart Anika Therapeutics Inc. ( ANIK NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Anika Therapeutics Inc.
ANIK Business Profile
Anika Therapeutics, Inc. (Anika), incorporated in 1992, develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. As of December 31, 2011, Anika’s wholly owned subsidiary, Anika Therapeutics S.r.l., had over 20 products commercialized, primarily in Europe. These products are also all made from hyaluronic acid, based on two technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA. The Company’s orthobiologics products consist of joint health and orthopedic products. These products are used in a range of treatments from providing relief from the pain of osteoarthritis, to regenerating damaged tissue, such as cartilage defects. Its joint health products include ORTHOVISC, ORTHOVISC mini, and MONOVISC. ORTHOVISC is available in the United States, Canada, Turkey and other international markets for the treatment of osteoarthritis of the knee, and in Europe for the treatment of osteoarthritis in all joints. ORTHOVISC mini is available in Europe, and is designed for the treatment of osteoarthritis in small joints. MONOVISC is its single injection osteoarthritis treatment indicated for all joints in Europe, and for the knee in Turkey and Canada. ORTHOVISC mini and MONOVISC are the Company’s two joint health products. In the United States, ORTHOVISC is indicated for the treatment of pain caused by osteoarthritis of the knee in patients, who have failed to respond adequately to conservative non-pharmacologic therapy and to simple analgesics, such as acetaminophen. It is a sterile, clear, viscoelastic solution of hyaluronan dissolved in physiological saline, and dispensed in a single-use syringe. The Company has a number of distribution relationships servicing international markets, including Canada, Europe, Turkey, the Middle East, Latin America, and Asia. It offers a number of additional products used in connection with orthopedic regenerative medicine. The products available in Europe include Hyalograft C Autograft for cartilage regeneration; Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells; Hyalonect, a woven gauze used as a graft wrap; and Hyaloss, HYAFF fibers used to mix blood/bone grafts to form a paste for bone regeneration. Anika S.r.l. also offers Hyaloglide, an ACP gel used in tenolysis treatment, but with potential for flexor tendon adhesion prevention, and in the shoulder for adhesive capsulitis with additional clinical data. Anika S.r.l.’s products are commercialized through a network of distributors, primarily in Europe, the Middle East, and Korea.